Menu
Search
|

Menu

Close
X

T2 Biosystems Inc TTOO.OQ (NASDAQ Stock Exchange Global Market)

6.63 USD
-0.27 (-3.91%)
As of 9:00 PM BST
chart
Previous Close 6.90
Open 6.89
Volume 124,400
3m Avg Volume 172,391
Today’s High 6.93
Today’s Low 6.61
52 Week High 9.98
52 Week Low 2.54
Shares Outstanding (mil) 35.14
Market Capitalization (mil) 157.07
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.57 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
2
FY17
5
FY16
4
FY15
3
EPS (USD)
FY18
-0.359
FY17
-1.940
FY16
-2.120
FY15
-2.208
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
40.38
5.73
Price to Book (MRQ)
vs sector
11.16
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
334.87
16.84
LT Debt to Equity (MRQ)
vs sector
323.80
12.51
Return on Investment (TTM)
vs sector
-113.02
14.61
Return on Equity (TTM)
vs sector
-328.67
16.34

EXECUTIVE LEADERSHIP

John McDonough
President, Chief Executive Officer, Director, Since 2007
Salary: $425,466.00
Bonus: --
Michael Cima
Co-Founder, Independent Director, Since 2006
Salary: --
Bonus: --
John Sprague
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Joanne Spadoro
Chief Operations Officer, Since 2016
Salary: --
Bonus: --
Alec Barclay
Senior Vice President - Operations, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Medical Equipment, Supplies & Distribution
Address:

101 Hartwell Ave
LEXINGTON   MA   02421-3125

Phone: +1781.4571200

T2 Biosystems, Inc. is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company's T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Company's initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements. The Company offers T2Dx Instrument (T2Dx) and the T2Candida Panel.

SPONSORED STORIES